Navigation Links
AstraZeneca Licenses Novel Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration
Date:2/9/2009

Agreement includes research collaboration to generate follow-up TRI compounds

WILMINGTON, Del., Feb. 9 /PRNewswire-FirstCall/ -- AstraZeneca, Mayo Clinic, and Virginia Tech Intellectual Properties Inc. today announced that AstraZeneca has licensed a portfolio of preclinical Triple Reuptake Inhibitor (TRI) compounds for depression. Researchers at Virginia Tech and Mayo Clinic collaborated to discover the compounds. The agreement provides AstraZeneca with a global license for all uses of the compounds, as well as exclusive manufacturing and commercial rights. It also establishes a research collaboration that will focus on jointly generating additional novel TRI compounds. Financial details were not disclosed.

Current classes of antidepressant therapies such as selective serotonin (SSRI) and dual serotonin/norepinephrine (SNRI) reuptake inhibitors are proven treatments for depression and anxiety. However, they only address the imbalances of one or two of the neurotransmitters in the brain.

Paul R. Carlier, Professor of Organic and Medicinal Chemistry at Virginia Tech, explains, "Together with our colleagues at Mayo Clinic, we have been seeking wider-spectrum behavior and have developed a portfolio of TRIs to address imbalances associated with the three major neurotransmitters. Besides incorporating all the benefits associated with serotonin and norepinephrine inhibition, our TRI compounds include the additional action of the dopamine neurotransmitter. We are excited to discover additional compounds that work through this unique mechanism."

Elliott Richelson, M.D., Mayo Clinic, co-inventor of the technology adds, "Through our clinical practice, we recognize the need for improved therapies to treat individuals suffering from depression or anxiety. The additional dopamine action of our TRI compounds has the potential to deliver a superior antidepressant in terms of greater
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. AstraZeneca Leads Local Walking Movement
2. AstraZeneca Joins Local Walking Movement
3. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
4. Verus Pharmaceuticals Announces Divestiture of Pediatric Asthma Development Programs to AstraZeneca
5. AstraZeneca Recognized as One of Working Mothers 100 Best Companies for the Sixth Consecutive Year
6. AstraZeneca Launches New Program to Support Facilities that Connect People to Needed Medical Care and Prescription Assistance
7. NPS Sells Assets Related to mGluR Collaboration to AstraZeneca for $30 Million to Support Late-Stage Product Development
8. Everett-Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca
9. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
10. AstraZeneca Response to November 2, 2007 Ruling In Re: Pharmaceutical Industry Average Wholesale Price Litigation, MDL No. 1456, U.S. District Court, District of Massachusetts
11. AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...7 Shamir Optical Industr...ovider of innovative products and technology to th... board of directors had declared a dividend distri...pproximately NIS 37.62 million based on the Novemb...pproximately US$ 0.609 (approximately NIS 2.3 base...
(Date:11/27/2009)...rade; announced today that Spectrum Health (Grand ...prise orthopedic templating solution and its Traum... (PRWEB) November 27, 2009 -- Voyant Health...d Rapids, Michigan) has licensed its TraumaCad Ent...umaCad Extend workflow solution, to allow its orth...
(Date:11/26/2009)...RNewswire/ -- The diabetes population in the Unite... and annual medical spending on the disease is pro...oday, according to a study published in the Decemb...ng Diabetes ® Program (NCDP), a program of No...om the University of Chicago. ,, According to t...
(Date:11/26/2009)... from the North Pole, Textsanta.net lets parents s..., North Pole, AK (PRWEB) -...s at the North Pole Santa Claus has added SMS text...e informed of his Christmas progress at the North ...nt have identified a large and growing percentage ...
(Date:11/25/2009)...wire-USNewswire/ -- When most people hear the acro...practor can also give patients the help they need....ch is where your jaw (mandible) contacts/connects ...ommon symptoms associated with TMJ dysfunction are.... But many other symptoms can be caused from TMJ ...
Breaking Medicine News(10 mins):Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2
...inois have found that a molecular pathway known to...humans is also critical to the pathology// of skel...d to advances in the palliative care of companion ...e of an enzyme, receptor activator of nuclear fact...
... not linked to a cluster of cases in Clendon, Sout...been treated for typhoid in Porirua and those case...edical officer of health, regional public health, ... the cases were in late January and one was early ...
...ies is expected to aid in longevity of life. This ...e Zutphen Study.// According to this study, a ...ular deaths and increase the life span in middle a...n body. This research studied the pattern of a...
... of losing weight. Belgium’s Janssen Animal Health...gs shed the flab.// The drug works by blocking...eat into their bloodstream. It does not affect t...y to beg for its favorite snack. Studies acros...
...nted by Finance minister P.Chidambaram has drawn c...his introductory remarks he// said: 'The education...funds. In 2007-08, I propose to enhance the alloca...ng has been a high priority and smokers have alway...
...ssue of the journal SLEEP finds that people with o... for cardiovascular disease.// The study att...ascular disease to heightened recognition and a ri... "There is abundant physiologic evidence imp...
Other Medicine News:Health News:Insights into Osteosarcoma in Cats and Dogs may Improve Palliative Care 2Health News:Union Budget: Impact on Health Sector 2Health News:Union Budget: Impact on Health Sector 3Health News:Sleep Well, Have a Healthy Heart ! 2
(Date:11/25/2009).... 25 /PRNewswire-Asia-FirstCall/ -- China Sky One,...pany") (Nasdaq: CSKI ), a,leading fully integrate...over-the-counter drugs in the People,s Republic of...ecently passed the Chinese National Institute for,...cts ("ICPBP") examination,for two of its new produ...
(Date:11/25/2009)...Newswire/ -- Reportlinker.com announces that a new...gue: ,, Mammography Equipment - A Global Mark...m/p0164330/Mammography-Equipment---A-Global-Market...t cancer in industrialized as well as developing n... the mammography market. Globally, escalating awar...
(Date:11/25/2009)...v. 25 Swissray International, Inc....phy ( ddR ) systems, announced today that its oper...tor with a long term view towards growing Swissray... all assets and intellectual property, as well as ... and growth Swissray is now poised to move to the ...
Breaking Medicine Technology:China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8Swissray International Announces New Ownership 2AMD LASERS Announces New Partnership with Dr Larry Rosenthal and Aesthetic Advantage 6460 1AMD LASERS Announces New Partnership with Dr Larry Rosenthal and Aesthetic Advantage 6460 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 6458 1Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 6458 2Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger 6458 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 1Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 2Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 3Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 4Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 5Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 6Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 7Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 8Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 9Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis 6455 10
The Closer
5.2F Supertorque Plus
Torcon NB Advantage
8F Standard
Medicine Products: